CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Oral ubrogepant in the acute treatment of migraine when administered during the prodrome (PRODROME) (NCT04492020)

Study title/design: Oral ubrogepant in the acute treatment of migraine when administered during the prodrome (PRODROME) (NCT04492020) Trial NCT04492020 Aim To evaluate the efficacy, safety and tolerability of oral ubrogepant in the acute treatment of migraine when administered during the prodrome Study design Adults aged 18-75 years randomised to ubrogepant 100 mg or placebo to …

Read more »

A Phase 1b, two-part, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between single dose erenumab or galcanezumab and multiple dose ubrogepant in participants with migraine (NCT0417974)

Study title/design: A Phase 1b, two-part, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between single dose erenumab or galcanezumab and multiple dose ubrogepant in participants with migraine (NCT0417974) Trial NCT0417974 Aim To evaluate the potential of a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab …

Read more »

A Phase 1 multicentre, double-blind, parallel-group trial of intermittent, high-frequency ubrogepant dosing in healthy adults

Ubrogepant (MK-1602) Study title/design: A Phase 1 multicentre, double-blind, parallel-group trial of intermittent, high-frequency ubrogepant dosing in healthy adults Trial n/a Aim To evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing to healthy participants. Study design Healthy adults (age 18-50 years) were randomised 1:1 to placebo or ubrogepant. …

Read more »

A Phase 3 multicentre, randomised, open-label extension study to evaluate the long-term safety and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura

Ubrogepant (MK-1602) Study title/design: A Phase 3 multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura Trial NCT02873221 Aim To evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year. …

Read more »

A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE I)

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE I) Trial NCT02828020 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for …

Read more »

A Phase 2 dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006)

Ubrogepant (MK-1602) Study title/design: A Phase 2 dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006) Trial NCT01613248: https://clinicaltrials.gov/ct2/show/NCT01613248 Aim To assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine. Study design Ubrogepant 1, 10, 25, 50 and 100 mg single …

Read more »

A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II)

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II) Trial NCT02867709 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for …

Read more »